Orudis KT sales of $28.7 mil. recorded in first two months on the market -- AHP data.
This article was originally published in The Tan Sheet
Executive Summary
ORUDIS KT SALES OF $28.7 MIL. IN FIRST TWO MONTHS on the market are reported by American Home Products in recent sales data for 1995. The new Rx-to-OTC switch analgesic began retail shipments on Nov. 8 and was expected to be widely available by November 17 ("The Tan Sheet" Nov. 20, p. 3).
You may also be interested in...
WYETH CORDARONE WILL BE $150 MIL. DRUG "SHORTLY", AHP SAYS; NEW CLINICAL TRIAL DATA WILL SUPPORT APPLICATION FOR PREVENTION OF ARRHYTHMIC DEATH INDICATION
Wyeth-Ayerst's anti-arrhythmic Cordarone is "going to go over the $150 mil. mark very shortly," American Home Products Exec VP Fred Hassan reported at AHP's R&D day in Pearl River, N.Y. March 28.
ELAN, ALZA DELIVER STRONG GAINS IN FIRST QUARTER AS FIRMS ENHANCE DRUG DEVELOPMENT EFFORTS; NOVARTIS MERGER SPAWNS RUMORS OF STILL MORE Rx DEALS
Elan's diversification from drug delivery into drug discovery has won the company an enthusiastic following on Wall Street. The stock posted a 32% gain for the first quarter, closing at 64-1/4.
Orudis KT sales of $28.7 mil. recorded in first two months on the market -- AHP data.
ORUDIS KT SALES OF $28.7 MIL. IN FIRST TWO MONTHS on the market are reported by American Home Products in recent sales data for 1995. The new Rx-to-OTC switch analgesic began retail shipments on Nov. 8 and was expected to be widely available by November 17 ("The Tan Sheet" Nov. 20, p. 3).